Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Ephraim Resources Equity-to-Asset Related Terms
Ephraim Resources Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Ephraim Resources's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Ephraim Resources's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ephraim Resources Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ephraim Resources's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Ephraim Resources's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Ephraim Resources's Equity to Asset Ratio for the fiscal year that ended in Jun. 2018 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ephraim Resources (ASX:EPA) has a Equity-to-Asset of -0.87 as of Dec. 2017. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Ephraim Resources and its competitors.
Is Ephraim Resources' Equity-to-Asset too high?
Ephraim Resources' current Equity-to-Asset is -0.87.
How does Ephraim Resources' Equity-to-Asset compare to competitors?
Ephraim Resources' Equity-to-Asset of -0.87 can be compared against companies in the Biotechnology industry. The industry median Equity-to-Asset is 0.68. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Ephraim Resources and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ephraim Resources's current Equity-to-Asset is -0.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ephraim Resources stock overvalued right now?
Ephraim Resources (ASX:EPA) has a current Equity-to-Asset of -0.87. The current Equity-to-Asset is -0.87. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Ephraim Resources (ASX:EPA), the current Equity-to-Asset is -0.87 as of Dec. 2017. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Ephraim Resources Ltd is an Australia-based company involved in agricultural biogenetics research and experimentation, licensing and consultancy, with a focus on nipah palm breeding, tissue culture, cultivation and plantation, and producing sugar syrup from nipah palm sap.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:EPA has been successfully added to your 
